Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | MicrobiomeTrials← Back to trialsNCT05358249
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2022-10-24Est. Completion: 2026-09-30
Enrollment target: 74 participants Locations- Massachusetts General Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- NYU School of Medicine, New York, New York, United States
- Novartis Investigative Site, Leuven, Belgium
- Novartis Investigative Site, Bordeaux, France
- Novartis Investigative Site, Lyon, France
- Novartis Investigative Site, Freiburg im Breisgau, Baden-Wurttemberg, Germany
- Novartis Investigative Site, Milan, MI, Italy
- Novartis Investigative Site, Singapore, Singapore
- Novartis Investigative Site, Seoul, South Korea
- Novartis Investigative Site, Barcelona, Spain
- Novartis Investigative Site, Madrid, Spain
- Novartis Investigative Site, Madrid, Spain
Other microbiome trials you might be interested in
KRAS Gene MutationRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Non-Small Cell Cancer AJCC v7
This phase II trial studies how well trametinib and docetaxel work in treating patients with stage IV KRAS mutation posi…
Anchorage, United StatesEst. completion May 15, 2019
Non-small Cell Lung Cancer
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participa…
Bakersfield, United StatesEst. completion Feb 19, 2029